

CLAIMS

WHAT IS CLAIMED:

1. A compound, wherein the compound is:




or


,


or a pharmaceutically acceptable salt, co-crystal or solvate thereof.

2. The compound of claim 1, wherein the compound is:



or the pharmaceutically acceptable salt, co-crystal or solvate thereof.

3. The compound of claim 1, wherein the compound is:



or the pharmaceutically acceptable salt, co-crystal or solvate thereof.

4. The compound of any one of claims 1-3, wherein positions represented as D of the compound have deuterium enrichment of at least 98%.
5. The compound of any one of claims 1-3, wherein positions represented as D of the compound have deuterium enrichment of at least 90%.
6. A pharmaceutical composition, comprising: a compound of any one of claims 1-5, and a pharmaceutically acceptable carrier.
7. A pharmaceutical composition according to claim 6 for use in treatment of a condition in a subject.
8. Use of a pharmaceutical composition according to claim 6 in the manufacture of a medicament for treating Parkinson's disease or a movement disorder associated with Parkinson's disease.

9. The use according to claim 8, wherein the movement disorder is dyskinesia.

10. The use according to claim 9, wherein the dyskinesia is levodopa-induced dyskinesia (LID).